In two independent studies, coadministration of the anti-VEGFR-2 CAR-T cells with exogenous IL-2 or TCR transduced cells significantly increased the tumor-free survival compared to anti-VEGFR-2 CAR-T cells alone in a melanoma murine model (Chinnasamy et al., 2010; Chinnasamy et al., 2013). Here, IL2 is linked to melanoma.